235 related articles for article (PubMed ID: 20713623)
21. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.
Ewer KJ; O'Hara GA; Duncan CJ; Collins KA; Sheehy SH; Reyes-Sandoval A; Goodman AL; Edwards NJ; Elias SC; Halstead FD; Longley RJ; Rowland R; Poulton ID; Draper SJ; Blagborough AM; Berrie E; Moyle S; Williams N; Siani L; Folgori A; Colloca S; Sinden RE; Lawrie AM; Cortese R; Gilbert SC; Nicosia A; Hill AV
Nat Commun; 2013; 4():2836. PubMed ID: 24284865
[TBL] [Abstract][Full Text] [Related]
22. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
[TBL] [Abstract][Full Text] [Related]
23. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
[TBL] [Abstract][Full Text] [Related]
24. A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
Fonseca JA; McCaffery JN; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
Vaccine; 2017 May; 35(24):3239-3248. PubMed ID: 28483199
[TBL] [Abstract][Full Text] [Related]
25. Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".
Ewer KJ; Sierra-Davidson K; Salman AM; Illingworth JJ; Draper SJ; Biswas S; Hill AV
Vaccine; 2015 Dec; 33(52):7444-51. PubMed ID: 26476366
[TBL] [Abstract][Full Text] [Related]
26. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.
Radosevic K; Rodriguez A; Lemckert AA; van der Meer M; Gillissen G; Warnar C; von Eyben R; Pau MG; Goudsmit J
Clin Vaccine Immunol; 2010 Nov; 17(11):1687-94. PubMed ID: 20826614
[TBL] [Abstract][Full Text] [Related]
27. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
Douglas AD; de Cassan SC; Dicks MD; Gilbert SC; Hill AV; Draper SJ
Vaccine; 2010 Oct; 28(44):7167-78. PubMed ID: 20937436
[TBL] [Abstract][Full Text] [Related]
28. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
[TBL] [Abstract][Full Text] [Related]
29. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
[TBL] [Abstract][Full Text] [Related]
30. Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.
Jäschke A; Coulibaly B; Remarque EJ; Bujard H; Epp C
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877929
[TBL] [Abstract][Full Text] [Related]
31. ΔE1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum.
Zong S; Kron MW; Epp C; Engler T; Bujard H; Kochanek S; Kreppel F
J Gene Med; 2011 Dec; 13(12):670-9. PubMed ID: 22095915
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
[TBL] [Abstract][Full Text] [Related]
34. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
[TBL] [Abstract][Full Text] [Related]
35. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa.
John CC; O'Donnell RA; Sumba PO; Moormann AM; de Koning-Ward TF; King CL; Kazura JW; Crabb BS
J Immunol; 2004 Jul; 173(1):666-72. PubMed ID: 15210830
[TBL] [Abstract][Full Text] [Related]
36. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ
PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500
[TBL] [Abstract][Full Text] [Related]
37. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
Daubenberger CA; Nickel B; Ciatto C; Grütter MG; Pöltl-Frank F; Rossi L; Siegler U; Robinson J; Kashala O; Patarroyo ME; Pluschke G
Eur J Immunol; 2002 Dec; 32(12):3667-77. PubMed ID: 12516559
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
Singh S; Kennedy MC; Long CA; Saul AJ; Miller LH; Stowers AW
Infect Immun; 2003 Dec; 71(12):6766-74. PubMed ID: 14638762
[TBL] [Abstract][Full Text] [Related]
39. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies.
de Koning-Ward TF; O'Donnell RA; Drew DR; Thomson R; Speed TP; Crabb BS
J Exp Med; 2003 Sep; 198(6):869-75. PubMed ID: 12963693
[TBL] [Abstract][Full Text] [Related]
40. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.
Woehlbier U; Epp C; Kauth CW; Lutz R; Long CA; Coulibaly B; Kouyaté B; Arevalo-Herrera M; Herrera S; Bujard H
Infect Immun; 2006 Feb; 74(2):1313-22. PubMed ID: 16428781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
